Indivior PLC $INDV Shares Sold by Clark Estates Inc. NY

Clark Estates Inc. NY lowered its stake in Indivior PLC (NASDAQ:INDV) by 24.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 153,600 shares of the company’s stock after selling 50,000 shares during the quarter. Indivior accounts for about 0.8% of Clark Estates Inc. NY’s portfolio, making the stock its 20th biggest holding. Clark Estates Inc. NY owned 0.11% of Indivior worth $3,703,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. CWM LLC purchased a new position in Indivior during the third quarter valued at $25,000. Raymond James Financial Inc. acquired a new position in shares of Indivior during the 2nd quarter worth about $26,000. Plato Investment Management Ltd purchased a new position in Indivior in the 3rd quarter valued at about $52,000. Blue Trust Inc. acquired a new stake in Indivior in the 3rd quarter worth about $99,000. Finally, Amalgamated Bank purchased a new stake in Indivior during the 2nd quarter worth approximately $61,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on INDV. Northland Securities set a $50.00 target price on Indivior in a research report on Tuesday, January 20th. Craig Hallum restated a “buy” rating and issued a $41.00 price objective on shares of Indivior in a report on Friday, October 31st. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a research report on Wednesday, January 28th. Finally, Morgan Stanley restated an “overweight” rating and set a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Insider Buying and Selling

In other news, Director Mark Stejbach purchased 775 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was acquired at an average price of $35.39 per share, with a total value of $27,427.25. Following the purchase, the director directly owned 16,847 shares in the company, valued at approximately $596,215.33. This represents a 4.82% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Barbara Ryan purchased 775 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director directly owned 1,963 shares in the company, valued at approximately $69,470.57. The trade was a 65.24% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 4,871 shares of company stock worth $172,385 over the last ninety days.

Indivior Stock Down 1.6%

NASDAQ INDV opened at $33.89 on Monday. The business’s fifty day simple moving average is $34.77 and its 200-day simple moving average is $29.71. The firm has a market cap of $4.24 billion, a PE ratio of 36.84 and a beta of 0.80. Indivior PLC has a 52 week low of $7.62 and a 52 week high of $38.00.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.